FDA cGMP Requirements for PET Drugs

被引：0

作者：

Norenberg, Jeffrey P.

Schwarz, Sally

VanBrocklin, Henry

机构：

来源：

JOURNAL OF NUCLEAR MEDICINE | 2011年 / 52卷 / 05期

关键词：

D O I：

暂无

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

引用

收藏

页码：16N / 16N

页数：1

相关论文

共 50 条

[31] FDA approval for PET colours without FDA listing
2000, MCM Publishing, London, Engl
[32] Trends in FDA post-marketing commitments and requirements for newly approved drugs, 2016-2021
Desai, Jayashri
Carsey, Jane C.
Thatcher, William
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 585 - 585
[33] FDA certifies recycled PET
Modern Plastics, 1993, 70 (06):
[34] The laboratory control system: Fulfilling cGMP requirements
Thomas, Elizabeth
Grochulski, Anita
Patel, Ripal
George, Sam M.
Zhang, Ling
BIOPHARM INTERNATIONAL, 2006, : 28 - 32
[35] Glaxo drugs seized by FDA
Mccoy, M
CHEMICAL & ENGINEERING NEWS, 2005, 83 (11) : 11 - 11
[36] Increased international requirements and FDA cuts
Immel, Barbara K.
BIOPHARM INTERNATIONAL, 2007, 20 (02) : 34 - +
[37] FDA Revamps Biosimilar Quality Requirements
Wechsler, Jill
BIOPHARM INTERNATIONAL, 2019, 32 (07) : 6 - 7
[38] FDA revamps biosimilar quality requirements
Wechsler, Jill
Pharmaceutical Technology, 2019, 43 (07) : 14 - 15
[39] FDA's NEPA requirements to continue
Paper Recycler, 1997, 8 (07):
[40] The FDA revises requirements for levothyroxine products
Burman, Kenneth
Hennessey, James
McDermott, Michael
Wartofsky, Leonard
Emerson, Charles
THYROID, 2008, 18 (05) : 487 - 490

← 1 2 3 4 5 →